This study was designed to explore the expression and the diagnostic value of
vascular endothelial growth factor (
VEGF) and soluble fms-like
tyrosine kinase-1 (sFlt-1) in pernicious
placenta previa (PPP) combined placental accreta/increta. A total of 140 PPP patients were enrolled and divided into two groups: 56 patients with
placenta accreta/increta (PA group), and 84 patients without
placenta accreta/increta (non-PA group). In the same period, 46 pregnant women without PPP who had undergone
caesarean section were selected as controls. The levels of
VEGF and sFlt-1 in serum were detected by
enzyme-linked
immunosorbent assay. Diagnostic efficiency of
VEGF and sFlt-1 in serum were evaluated by receiver operating characteristics curve. It was found that both
VEGF and sFlt-1 had diagnostic value for PPP and
placenta accreta/increta combined PPP. In addition, the levels of
VEGF and sFlt-1 could be used to distinguish
placenta accreta from
placenta increta.
VEGF was negatively correlated with sFlt-1 in PPP patients. In summary, the levels of
VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between
placenta accreta and increta.KEY POINTSThe levels of
VEGF and sFlt-1 could be used to distinguish
placenta accreta from
placenta increta.
VEGF is negatively correlated with sFlt-1 in PPP patients.The levels of
VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between
placenta accreta and increta.